Author: healthadmin

Typically, at major pharmaceutical companies’ earnings conferences, executives talk enthusiastically about new products and tout expectations for blockbusters. But patent defense took center stage during Sanofi’s first quarter presentation. A big question for the French company is how to overcome Dupixent’s loss of exclusivity (LOE) when the immunology superstar’s intellectual property expires in the United States. Instead of pointing to pipeline candidates that could fill the void, Sanofi emphasized that it has a “robust defense plan” to extend Dupixent’s exclusivity beyond March 2031, when the U.S. patents protecting Dupixent’s compound expire (PDF). Sanofi said in an investor presentation that issued…

STAT+ exclusive story Already have an account? Log in This article is exclusive to STAT+ subscribers Already have an account? Log in Individual plan Group plan See all plans To read the rest of this story, subscribe to STAT+. Subscribe Source link

And there was nothing. Regeneron’s announcement of a drug pricing agreement with the White House on Thursday means all 17 companies targeted in a series of letters by the Trump administration last year have agreed to abide by the president’s “most-favored-nation” strategy. Regeneron, which now joins the ranks of MFN policy proponents ranging from Novo Nordisk and Eli Lilly to Gilead, Roche and Novartis, has pledged to lower the prices of its drugs on Medicaid, in line with other developed countries. Regeneron is also committed to matching the cost of future treatments with prices “set in a defined group of…

A small experimental study conducted in Germany compared the topic knowledge that medical students learned by producing podcasts with the topic knowledge they learned by listening to podcasts. However, the overall results were inconclusive, as one group showed better knowledge about the topic they podcasted about, while the other group saw no difference between the two learning methods. The paper was published in clinical teacher. A podcast is a digital audio program that you can listen to on your phone, computer, or other device. These are usually released as episodes, as series focused on a specific topic. Podcasts can be…

Travis Smith was a very serious baby. His mother, Sierra, who was born completely deaf, struggled to see his personality shine through in a silent world. “My son was 100% deaf,” Smith told Fierce Biotech. “I didn’t say Mama, and I didn’t even know she had a name.” But that all changed last June when Travis underwent surgery to undergo Regeneron Pharmaceuticals’ experimental gene therapy DB-OTO. Just a few months later, Travis’ world literally started singing. “He loves playing his little guitar. He loves listening to Bruno Mars,” Smith said of her son, now 2 1/2 years old. “I’m really…

Him & Hers announced Thursday that eligible users now have access to the full line of U.S. Food and Drug Administration (FDA)-approved GLP-1 drugs on its platform. Healthcare providers will now be able to send prescriptions for Eli Lilly’s Zepbound, Mounjaro, and oral Foundayo to LillyDirect pharmacies, giving users access to out-of-pocket pricing. The direct-to-consumer telemedicine platform began offering Wegovy tablets and injections, as well as Ozempic injections, in late March. According to the telemedicine company’s website, here’s a breakdown of the lowest monthly out-of-pocket costs for each drug: Foundayo Pill: Starting at $149/monthMunjaro: $1,899 per monthOzempic: Starting at $199/monthWegovy…

The magnitude of the currency headwinds in Roche’s first-quarter earnings report caught many off guard, but the company’s earnings call also featured a lot of discussion about oral SERD drug Gylidestrant, which remains a key pipeline prospect. The drug has blockbuster ambitions, but incomplete clinical data cloud its path to commercialization. In a high-profile Phase 3 failure, diredetrant recently failed in first-line HR-positive, HER2-negative breast cancer, casting doubt on Roche’s multibillion-dollar ambitions for oral SERD. But on a conference call Thursday, Roche Pharmaceuticals CEO Teresa Graham dismissed the impact of the front-line setbacks and said there was still a good…

Heart disease and cancer are the leading causes of death in the United States, but cancer rarely progresses to the heart. This is a finding that clinicians appreciate, but it is largely inexplicable. But in a paper published Thursday in the journal Science, researchers propose one possible explanation. The theory is that the organs are under constant pressure as they beat thousands of times a day and pump out gallons of blood, creating an environment ripe for cancer. Although the study, conducted in mice, is preliminary, outside experts said it points to a potential new approach to cancer treatment. “What’s…

The days of “Just Say No” seem long gone. Over the weekend, President Trump signed an executive order increasing the availability of certain psychedelic drugs as treatments for mental illnesses, ordering $50 million in spending and expedited review for approval by the Food and Drug Administration. At one point, the president joked to a motley crowd of government officials, former Navy SEALs and podcaster Joe Rogan, “Can I have a little bit?” The Trump administration announced Wednesday that it has downgraded medical marijuana from its top status as a controlled substance and is asking the Drug Enforcement Administration to do…

Recent research published in journals dream It suggests that our dreams function as complex simulation spaces in which we practice coping with social challenges. These findings provide evidence that deep-rooted social impulses that guide our waking lives, such as protecting reputation and caring for family, also organize our nighttime visions. This study shows that dreams are not just random images, but are structured around the same basic needs that have helped humans survive for generations. Most previous research on sleep has focused on narrow functions. Some scientists suggest that dreams simply help us practice preparing for physical danger or help…